Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
The MaxCyte VLX Large Scale Transfection System for Protein and Antibody Production is Launched at PepTalk 2012
January 10, 2012
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at CHI's PepTalk 2012 being held January 9-13 in San Diego. The highlighted event will be the introduction of the MaxCyte® VLX™ Large Scale Transfection System which has the capability to transfect up to 2E11 cells in less than 30 minutes with high efficiency and high viability, dramatically extending the gram-scale protein bioproduction capabilities of the current MaxCyte instrument product line.
"We are delighted to announce this major expansion of the MaxCyte instrument portfolio at PepTalk 2012, introducing the MaxCyte VLX for very large scale transient transfection for protein production in any desired cell type, including CHO and Vero. The MaxCyte VLX dramatically increases the volume capability of our product line, enabling 200 billion cell transfection runs for the production of recombinant proteins, antibodies, virus-like particles (VLPs), virus-replicon particles (VRPs), and toxic and apoptotic proteins using the same patented flow electroporation platform as the well-proven MaxCyte® STX™ Scalable Transfection System," says Douglas Doerfler, President and CEO of MaxCyte. "Companies look to MaxCyte to help them shorten their product development timelines. By using the MaxCyte instrument platform for cell transfection, companies now have the unprecedented capability to produce multi-gram quantities of proteins in any appropriate manufacturing host background, including CHO, in just a few short weeks rather than the many months currently required for the development and re-development of stable cells lines."
In addition, on Wednesday, January 11 at 12:15 PM at PepTalk 2012, Dr. James Brady, Director of Technical Applications at MaxCyte, will deliver a podium presentation entitled, Accelerating Biotherapeutic Development Pipelines by Producing Gram-level Quantities of Antibodies Using Large-volume, Transient Transfection of CHO Cells. The Company will also present a poster on third party generated data, lead a roundtable "buzz" discussion session, and schedule one-on-one consultations at their exhibition booth #38 to demonstrate how the MaxCyte flow electroporation technology can improve the timelines and biological relevance of protein and antibody development.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot scale.